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Blue dye for identification of sentinel nodes in breast cancer and malignant 1 
melanoma: a systematic review 2 
Abstract 3 
The combined technique (radioisotope and blue dye) is the gold standard for sentinel lymph 4 
node biopsy (SLNB) and there is wide variation in techniques and blue dyes used. We 5 
performed a systematic review to assess the need for radioisotope and the optimal blue dye 6 
for SLNB. A total of 21 studies were included. The SLNB identification rates are high with all 7 
the commonly used blue dyes. Furthermore, methylene blue is superior to iso-sulphan blue 8 
and Patent Blue V with respect to false negative rates. The combined technique remains the 9 
most accurate and effective technique for SLNB. In order to standardise the SLNB technique, 10 
comparative trials to determine the most effective blue dye and national guidelines are 11 
required. 12 
Keywords 13 
Sentinel lymph node biopsy (SLNB); Combined technique; Radioisotope; Blue dye; 14 
Methylene blue; Patent Blue V; Iso-sulphan blue; Breast; Malignant melanoma.  15 
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Introduction 1 
Sentinel lymph node biopsy (SLNB) has been used in breast cancer and malignant melanoma 2 
for surgical lymph nodal staging since the early 90’s [1]. The standard technique for 3 
localising sentinel lymph nodes is the combined technique of radioisotope (99mTc) and blue 4 
dye injected into the breast or near the melanoma site, however there is wide variation in 5 
dyes and techniques used [2]. SLNB was first performed using a radioisotope injection in 6 
1993 by Krag et al. [3]. Blue dye was first reported in 1992 when Morton et al. used iso-7 
sulphan blue (Mylan Institutional LLC, United States) and Patent Blue V (Guerbet, France) for 8 
SLNB in 223 patients, obtaining an identification rate of 82% [1]. By using a combination of 9 
both techniques a higher identification rate is achievable [4, 5]. In experienced hands high 10 
identification rates of up to 96% are achieved with blue dye alone [6]. 11 
The use of radioisotopes creates logistical challenges for hospitals, including the handling 12 
and disposal of radioisotopes, training of staff, and legislative requirements. These factors in 13 
addition to lack of access to radioisotopes, have limited the uptake of SLNB worldwide. 14 
Although the incidence of cancer is rising, the use of the SLNB procedure has reached a 15 
plateau, with around 60% of an estimated 500,000 patients in developed countries having 16 
access to the procedure. This figure falls to 5% in China and is even lower in the rest of the 17 
world [7-9]. So for developed countries were radioisotopes are readily available, there is 18 
interest in eliminating blue dye and using radioisotope on its own but current evidence 19 
suggests SLN identification rate is significantly lower with radioisotope alone. Whereas 20 
worldwide and in developing countries, where there is limited or no access to radioisotopes, 21 
there is interest in using blue dye alone and in ascertaining which is the optimal blue dye to 22 
use. 23 
The most common blue dyes used in SLNB are iso-sulphan blue 1%, Patent Blue V sodium 24 
2.5% and methylene blue 1% (figure 1); other dyes such as indigocarmine or indocyanine 25 
have been used in the Far East due to lack of availability to other blue dyes [5, 10]. Iso-26 
sulphan blue, otherwise known as lymphazurin blue, is an isomer of Patent Blue V which has 27 
two different constituents, a calcium and a sodium based salt, the latter being used in SLNB 28 
[5]. Iso-sulphan blue has been applied as a colouring agent in textiles, cosmetics and the 29 
paper and leather industry [11]. It binds to albumin and other local proteins and is absorbed 30 
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by the lymphatic system, which makes it suitable for SLNBs [12]. Adverse events such as 1 
interference with the pulse oxygen oxymetry, blue tattooing of the skin, discoloration of 2 
body fluids and anaphylactic and allergic reactions have been reported in the literature [11-3 
18]. A skin test can be performed to detect any hypersensitivity but it lacks sensitivity [15-4 
17]. 5 
Patent Blue V dye has been used for food colouring, cosmetics, textiles and in the paper 6 
industry [19]. It is recommended by the Association of Breast Surgery for use in SLNB in the 7 
United Kingdom [2, 20]. It shares similar mechanisms of action and adverse events with iso-8 
sulphan blue [19, 21, 22]. Patent Blue V is also known by the names alphazurine, sulfan blue, 9 
sulphane blue, Patent blue violet and Patent blue pure [5]. 10 
Methylene blue (Akorn, United Kingdom; American Regent, United States; and Colonis 11 
Pharma, United Kingdom) is a dark green crystalline compound, which becomes dark blue in 12 
solution [5]. It has been commonly used in medicine in both diagnostic and therapeutic 13 
procedures [5]. It also has been used in resuscitation to improve the outcomes in patients 14 
with hypovolemic states [23]. Due to the wider availability and lower cost, many centres 15 
have changed their practice to methylene blue [24-26]. 16 
Kim et al. [27] published a systematic review in which 69 trials were evaluated performing 17 
SLNB followed by axillary lymph node clearance for early breast cancer and concluded that 18 
the combined technique has a better identification rate compared to the radioisotope or 19 
blue dye techniques alone. Furthermore, Valsecchi et al. [28] performed a meta-analysis of 20 
71 studies which used SLNB for staging of malignant melanoma and found a mean 21 
identification rate of 98.1% and a mean false negative rate of 12.5% supporting the use of 22 
SLNB for staging patients with malignant melanoma. However, five-ten years later, there are 23 
still no national or international guidelines pertaining to standards of using the combined 24 
radioisotope and blue dye technique in SLNB. 25 
We performed a systematic review to assess the need for radioisotope and the optimal blue 26 
dye for SLNB in breast cancer and malignant melanoma. This systematic review was 27 
performed to assess the need for radioisotope and the optimal blue dye for SLNB in breast 28 
cancer and malignant melanoma. There is currently no standardised technique for SLNB, as 29 
several blue dyes are used and some centres have stopped using radioisotope or blue dye 30 
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altogether, even though several systematic reviews have demonstrated the superiority of 1 
the combined technique. 2 
Materials and Methods 3 
Study selection 4 
A systematic review of the literature was performed using PubMed and Medline databases 5 
to identify all studies published up to June 2015 evaluating the role of blue dyes for SLNB. 6 
The MESH terms used were sentinel AND node AND cancer AND any combination of blue 7 
dye, methylene blue (MBD), isosulph* blue (IBD), Patent Blue (PBD), indigocarmine (IDC), 8 
sulphan blue, sulphane blue, patent violet or patent pure. We required reports to be in the 9 
English language and the subjects to be human. To broaden the search the related articles 10 
function was used. References of included articles were searched by hand to broaden the 11 
search. The last search was conducted on June 26th, 2015. 12 
Inclusion criteria 13 
Studies were eligible if they met the following criteria: (1) studies performed on human 14 
subjects with breast cancer or malignant melanoma, (2) studies including radioisotope in a 15 
comparative arm (3) studies including blue dye in both comparative arms, (4) studies 16 
describing the identification rate and/or (5) studies describing the complication rates. For 17 
studies with overlapping study populations, only the most recent study was included. 18 
Exclusion criteria 19 
Studies were excluded if they failed to meet the inclusion criteria. Studies in which all 20 
patients had SLNB with the same technique, studies with inconsistent injection site and/or 21 
studies reporting on less than 50 patients were excluded. Studies using different types of 22 
radioisotope, indocyanine green or magnetic dye were excluded as lymph nodes localised 23 
with these technique cannot be identified solely by direct vision. Letters, editorials and case 24 
reports were also excluded from the study. 25 
Data extraction 26 
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Each study was evaluated for either inclusion or exclusion. One reviewer, (M.P.) extracted 1 
data from all selected studies and a second reviewer (P.C.) verified the accuracy of the 2 
extracted data. In case of a disagreement, the senior author (M.D.) made the final decision. 3 
Risk of bias in individual studies 4 
To determine the suitability of randomised controlled trials (RCTs), the “Risk of bias” tool, as 5 
described in the Cochrane Handbook [29] was used. The quality of cohort studies was 6 
assessed according to the guidelines of the Strengthening the Reporting of Observational 7 
Studies in Epidemiology (STROBE) statement [30]. Six items of the amended STROBE 8 
statement were considered relevant for quality evaluation. Studies with a score of less than 9 
four were excluded. Two reviewers (M.P. and P.C.) independently performed the 10 
assessment. In case of discordance, the senior author (M.D.) made the final decision. 11 
Statistical analysis 12 
All extracted data were tabulated, synthesized and presented as means and percentages. 13 
Numerators and denominators were provided to address outcomes of included studies. For 14 
continuous variables the mean ± standard deviation (SD), median and range were extracted 15 
and reported where available. The false negative rate was defined as the percentage of 16 
involved nodes missed with respectively the combined or the blue dye technique alone. 17 
Meta-analysis was performed using network analysis, with two random effects (correcting 18 
for blue dye and radioisotope) using maximum likelihood via a purpose written FORTRAN 19 
program. The probabilities were presented in probability ± standard error (95% confidence 20 
interval limits). 21 
Results 22 
Selected studies 23 
A total of 1825 articles published up to June 2015 were identified from the literature search 24 
(figure 2). Searching through references of included articles identified four further articles. 25 
After reviewing the titles and abstracts, 1722 articles were excluded and 107 articles 26 
underwent full text examination. A total of 22 articles fulfilled the inclusion criteria. 27 
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However, one study [31] reported on less than 50 patients and therefore was excluded, 1 
resulting in a total of 21 studies [24, 32-51] deemed eligible for further analysis. 2 
Study characteristics 3 
A total of 21 studies with 6082 clinically node negative patients and 6133 SLNBs were 4 
included in this systematic review. Eligible studies encompassed 11 prospective studies [24, 5 
33, 35, 37-39, 46-48, 50, 51], six retrospective studies [32, 34, 36, 40, 42, 49], three 6 
randomised studies [43-45] and one RCT [41]. The mean age was 55.7±2.2 (17-87 years, 12 7 
studies (2082 patients)) [24, 34, 35, 37, 39-41, 45, 46, 48, 50, 51]. SLNB was performed for 8 
staging of the axilla in clinically node negative patients with breast cancer in 18 studies [24, 9 
33-39, 41, 42, 44-51] and melanoma in three studies [32, 40, 43]. Studies on melanoma 10 
included 441 patients with melanomas located in the head and neck, upper and lower 11 
extremities and torso. Tumour characteristics and the type of surgery were not reported 12 
[32, 40, 43]. In studies on breast cancer, 1615 patients (28.6%) were diagnosed with invasive 13 
carcinoma, 92 patients (1.6%) with non-invasive carcinoma and the tumour type was not 14 
reported in 3934 patients (69.7%). Breast conserving surgery was performed in 633 patients 15 
(11.2%), mastectomy in 560 patients (9.9%) and the type of surgery was not reported in 16 
4448 patients (78.9%). SLNBs in patients with breast recurrence were not included or not 17 
reported in the studies. 18 
All studies used the radioisotope technique in a proportion of patients. The radioisotope 19 
was injected between 1-7 days before surgery in one study [43], on the day prior to surgery 20 
in ten studies [33-35, 37, 40, 42, 45, 48-50], on the morning of surgery in five studies [39, 41, 21 
46, 47, 51] and the time of injection was not reported in five studies (table 1) [24, 32, 36, 38, 22 
44]. The radioisotope was injected peri-tumorally in 11 studies [24, 33, 35-38, 42, 45, 48, 49, 23 
51], intra-dermally in four studies [32, 40, 43, 47], subdermally in three studies [34, 41, 50], 24 
peri-areolarly in one study [39] and not reported in two studies [44, 46]. In 12 studies [32-25 
34, 37, 38, 40, 43, 46-50] between 0-1mCi of radioisotope was injected, more than 1mCi was 26 
injected in four studies [35, 36, 45, 51], between 1-2ml in two studies [24, 42] and not 27 
reported in three studies. 28 
Patent Blue V was used in ten studies [33, 35, 38-41, 45, 48, 49, 51], methylene blue in six 29 
studies [24, 34, 37, 39, 43, 50] and iso-sulphan blue in eight studies [24, 32, 36, 42-44, 46, 30 
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47]. The blue dye was injected on the morning of surgery in one study [49], just prior to 1 
surgery in 18 studies [24, 32-35, 37-43, 45-48, 50, 51] and the time of injection was not 2 
reported in two studies (table 1) [36, 44]. Blue dye was injected peri-tumorally in 12 studies 3 
[24, 33, 35, 36, 38, 42, 45-49, 51], sub-areolarly in three studies [37, 39, 50], intra-dermally 4 
in three studies [32, 40, 43], subdermally in two studies [34, 41] and was not reported in 5 
one study [44]. Between 0-1ml of blue dye was injected in five studies [32, 36, 40, 41, 50], 1-6 
2 ml in six studies [35, 39, 43, 45, 48, 49], 2-5 ml in eight studies [24, 33, 37, 38, 42, 46, 47, 7 
51], more than 5 ml in one study [34] and one study [44] did not report on the injected 8 
dose.  9 
Patent Blue V alone was compared to the combined technique in nine studies [33, 35, 38, 10 
40, 41, 45, 48, 49, 51], iso-sulphan blue alone was compared to the combined technique in 11 
six studies [32, 36, 42, 44, 46, 47] and methylene blue alone was compared to the combined 12 
technique in three studies [34, 37, 50]. 13 
Methylene blue was compared to iso-sulphan blue in two studies [24, 43] and was 14 
compared to Patent Blue V in one study [39]. All three studies [24, 39, 43] were performed 15 
with radioisotope injected in all patients.  16 
Quality assessment 17 
Six criteria of the amended STROBE statement [30] were used to perform a quality 18 
assessment of the included cohort studies (table 2a). All studies stated their study objectives 19 
and all but one study [36] reported on clear inclusion criteria. The SLNB technique was 20 
standardised in all but three studies [24, 32, 49] and standardised histopathology was not 21 
used in five studies [33, 34, 42, 45, 51]. Patients were followed-up after surgery in two 22 
studies [32, 40] and one study [40] reported on incomplete data which caused withdrawals 23 
from the study. The overall STROBE score was 4.6±0.5 (4.0-5.0). Three studies [35, 38, 44] 24 
used previously published information which described all relevant information. 25 
The Cochrane checklist [29] was used to determine the quality of the RCT [41] (table 2b). 26 
Adequate sequence generation was present, patients were randomised and a power 27 
analysis was performed. Concealed allocation was not applied and blinding was not possible 28 
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due to different injection procedures. Incomplete data were not addressed and selective or 1 
other biases were not found. The study had a mean score of 5.0. 2 
Outcomes 3 
SLNB identification rate 4 
The identification rate of the combined technique was 95.0±5.7% (82-100%) and with blue 5 
dye alone 86.2±10.0% (65-98%; tables 3 and 4). The identification rate by the type of blue 6 
dye was 83.2±10.3% (65-96%) [33, 35, 38, 40, 41, 45, 48, 49, 51] with Patent Blue V, 7 
92.7±8.4% (83-98%) [34, 37, 50] with methylene blue and 86.7±9.3% (73-98%) [32, 36, 42, 8 
44, 46, 47] with iso-sulphan blue. Combining blue dye with radioisotope showed an 9 
identification rate of 94.7±5.6% (83-100%) [33, 35, 38-41, 45, 48, 49, 51] with Patent Blue V, 10 
97.7±2.3% (94-100%) [24, 34, 37, 39, 43, 50] with methylene blue and 93.4±7.0% (82-100%) 11 
[24, 32, 36, 42-44, 46, 47] with iso-sulphan blue. 12 
Setting the random effects to zero, it appears that the blue dyes differ in probability of 13 
identifying a node, with methylene blue having a greater probability than Patent Blue V 14 
(p=0.0122). Including random effects for the radioisotope and the blue dye shows that there 15 
is no evidence that the three blue dyes differ in probability of identifying a node, with 16 
probabilities (± standard error (95% confidence interval)) of 0.945±0.0059 (0.933, 0.956), 17 
0.946±0.0082 (0.929, 0.961) and 0.942±0.0082 (0.925, 0.958) for respectively iso-sulphan 18 
blue, methylene blue and Patent Blue V. The mean probability that the radioisotope will 19 
detect nodes which have not been detected by blue dye is 0.610±0.0352 (0.546, 0.684). 20 
The identification rate when using blue dye alone was 85.3%±10.2% in the breast studies 21 
and 90.0%±0.0% in the melanoma studies. Adding radioisotope gives identification rates of 22 
94.2%±5.7% and 99.0%±2.0% respectively. An additional term was added to the log-odds 23 
ratio to determine if a melanoma study caused any difference in the identification rate and 24 
this showed no significance (p=0.55). Hence we performed analysis on both breast and 25 
melanoma studies together.  26 
Lymph node retrieval rate per patient 27 
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Mean lymph node retrieval rate per patient was 1.8±0.3 nodes (1.3-2.5 nodes) for the 1 
combined technique whereas for blue dye alone it was 1.6±0.3 nodes (1.1-2.1 nodes; table 2 
3). By type of blue dye, mean lymph node retrieval rate per patient was 1.5±0.3 nodes (1.1-3 
1.8 nodes) [33, 35, 40, 41, 48, 49] with Patent Blue V, 1.7±0.2 nodes (1.5-1.9 nodes) [34, 37, 4 
50] with methylene blue and 1.8±0.4 nodes (1.4-2.1 nodes) [32, 42, 46] with iso-sulphan 5 
blue. When combined with radioisotope the mean lymph node retrieval rate per patient 6 
was 1.7±0.3 nodes (1.3-2.1 nodes) [33, 35, 40, 41, 48, 49] with Patent Blue V, 1.9±0.4 nodes 7 
(1.6-2.5 nodes) [24, 34, 37, 50] with methylene blue and 1.8±0.3 nodes (1.4-2.0 nodes) [24, 8 
32, 42, 46] with iso-sulphan blue. 9 
The node retrieval rates were 1.62±0.3 nodes for the breast studies and 1.40±0.0 with the 10 
melanoma studies with blue dye alone and 1.78±0.34 nodes versus 1.65±0.35 nodes with 11 
blue dye and radioisotope, respectively.  12 
False negative rate 13 
The mean false negative rate (missed involved nodes not detected during SLNB but with 14 
axillary node clearance) of the blue dye alone technique was 11.5±7.4% (0-23%) [33-37, 41, 15 
42, 44, 45, 48-50]. For the combined technique the mean false negative rate was 7.5±8.7% 16 
(0-33%) [33-37, 40-42, 44, 45, 48-50]. Looking at the blue dyes separately, the mean false 17 
negative rate for Patent Blue V was 9.9±8.4% (4-23%) [33, 35, 41, 45, 48, 49], methylene 18 
blue 6.4±8.2% (4-16%) [34, 37, 50] and iso-sulphan blue 13.3±2.0% (11-15%) [36, 42, 44]. 19 
With random effects it is seen that the probabilities of a false negative for iso-sulphan blue 20 
and Patent Blue V differ significantly from methylene blue. Hence, methylene blue has 21 
significantly fewer false negative nodes than either of the other blue dyes, with probabilities 22 
of 0.076±0.022 (0.026, 0.113), 0.027±0.009 (0.011, 0.046) and 0.055±0.016 (0.021, 0.084) 23 
for respectively iso-sulphan blue, methylene blue and Patent Blue V. The mean probability 24 
for a false negative node with radioisotope is 0.524±0.114 (0.179, 0.740). 25 
The blue dyes alone have probabilities of 0.146±0.015 (0.119, 0.018), 0.0523±0.014 (0.0304, 26 
0.0829) and 0.106±0.024 (0.067, 0.159), respectively. 27 
Breast studies using blue dye only had a false negative rate of 11.5%±7.4%. No studies with 28 
melanoma reported false negative rates for blue dye alone. With addition of radioisotope 29 
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the false negative rate was 5.4%±4.0% for breast and 33%±0.0% for melanoma. No 1 
difference was seen between breast and melanoma studies due to a lack of information on 2 
false negative rates in melanoma studies.  3 
Histopathology 4 
Histopathologic characteristics are shown in table 3 and 4. A total of 4093 patients (67.3%) 5 
had normal SLNs, 1698 patients (27.9%) involved SLNs (micro- or macro-metastases) and for 6 
291 patients (4.8%) nodal involvement was not reported. The proportion of macro- and 7 
micro-metastases was not reported in almost all articles. 8 
Out of the 1698 patients with involved nodes, 555/2433 patients (22.8%) treated with iso-9 
sulphan blue, 192/726 patients (26.4%) with methylene Blue and 831/2322 patients (35.8%) 10 
with Patent Blue V had involved nodes. In one comparative study [39] no separation was 11 
made for involved nodes between the two blue dye groups. 12 
Adverse event and recurrence rates 13 
Adverse events were documented in five studies [34, 38-40, 43]. Three studies [34, 40, 43] 14 
reported no adverse events and two studies [38, 39] reported allergic reactions in 0.2% 15 
(3/1824, Patent Blue V, peri-tumorally injection of 2-5 ml), local inflammation at the 16 
injection site in 0.3% (6/1824, five methylene blue and one Patent Blue V, sub-areolar 17 
injection of 1-2ml) and skin discoloration in 3.2% (59/1824, 22 methylene blue and 37 18 
Patent Blue V, sub-areolar injection of 1-2ml).  19 
Tumour recurrence was documented in three studies [32, 40, 49] of which two studies [32, 20 
49] did not found any recurrence and one study [40] reported on recurrence in 1.4% 21 
(9/644).  22 
Discussion 23 
The combined technique has a high mean identification rate of 95.0±5.7%, a lymph node 24 
retrieval rate of 1.8±0.3 nodes per patient and a false negative rate of 7.5±8.7%. It should be 25 
used by centres with access to radioisotopes as standard of care. For blue dye alone, the 26 
mean identification rate was 86.2±10.0%, lymph node retrieval rate was 1.6±0.3 nodes per 27 
patient and false negative rate was 11.5±7.4%. Blue dye alone is an inferior technique to the 28 
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combined technique and the blue dye technology still has a long way to go to be perfected. 1 
This can be done by improving the type of blue dye and by further identifying the anatomy 2 
of the lymph nodes [52]. 3 
Several articles reported a learning curve associated with using blue dye for SLNB [33, 35, 4 
37, 41, 46, 47]. The more recent published literature does not report on the learning curve 5 
or correct for it, which would explain the observed differences in identification and false 6 
negative rates. Also, not all studies performed lymph node clearance, which would enable a 7 
more accurate assessment of false negative rate.  8 
The outcomes also differed with type of blue dye used. The identification rates were highest 9 
with methylene blue (92.7±8.4%) and lowest with Patent Blue V (83.2±10.3%); lymph node 10 
retrieval rates were lowest with Patent Blue V (1.5±0.3) and highest with iso-sulphan blue 11 
(1.8±0.4); false negative rates were lowest with methylene blue (6.4±8.2%) and highest with 12 
iso-sulphan blue (13.3±2.0%). The diversity in identification rates for the different blue dyes 13 
could also be attributed partially to differences in surgeons’ learning curve, as this was not 14 
reported in the included studies. 15 
Methylene blue had the highest identification rates and lowest false negative rates 16 
suggesting that it may be superior to the other blue dyes. Statistical analysis confirmed that 17 
methylene blue is superior to the other blue dyes with respects to false negative rates. For 18 
the identification rates, it appeared that methylene blue was superior as well, however, 19 
after adding two random effects it was shown that there was no significant difference 20 
between the blue dyes in terms of identification rates. Only three studies (670 patients) 21 
compared different blue dyes and larger studies are required in order to standardise the 22 
SLNB technique. This is particularly important from a clinical perspective (avoidance of wide 23 
variations in SLNB technique) and for future trials comparing novel tracers against the 24 
combined technique. 25 
The ideal blue dye would be the dye with the highest identification rate but also with the 26 
lowest adverse event rate. This is predominantly important in large breast cancer centres 27 
where even a low incidence of anaphylaxis could significantly impact on practice. In remote 28 
centres or satellite day-surgery centres, a small but significant risk of anaphylaxis is an 29 
important issue. The incidence and severity of adverse events following injection were 30 
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under reported and only described in five out of 21 studies (1824 patients). The allergic 1 
reaction rate of 0.2% (3/1824) is lower than the 1% rate reported by both the ALMANAC 2 
trial and NEW START [10, 53]. Tattooing of the skin is rarely reported suggesting that this is 3 
not of particular concern to patients or clinicians. There is insufficient evidence to compare 4 
the incidence of allergic reactions between the different blue dyes. 5 
There is wide variation in dyes and techniques used for SLNB [2]. National guidelines for 6 
SLNB are recommended in order to ensure correct documentation of technique and 7 
reporting of adverse events. Furthermore it would resolve the current wide variation in blue 8 
dyes used. Patent Blue V is currently licensed as a medical product in France. Irrespectively, 9 
it is the most common blue dye used for SLNB in some countries, for instance in the UK. Iso-10 
sulphan blue is used in North America and less often in Europe as it is unlicensed. 11 
Methylene blue dye is CE-marked as an injectable device with one the indications for use 12 
being visualisation of sentinel lymph nodes (Colonis Pharma Ltd, UK). Despite this, it is not 13 
often used for SLNB in the UK. Furthermore in a cost effectiveness performed by Gold et al. 14 
[54] it was shown that methylene blue is much more cost effective compared to iso-sulphan 15 
blue and the costs are also lower compared to Patent Blue V. This is potentially important in 16 
developing were lack of access to radioisotope prevents introduction to SLNB [7]. 17 
The current combined technique has a mean SLN identification rate of 97% in breast cancer 18 
and 98.1% in malignant melanoma [10, 28, 53]. Hence, finding a non-inferior surrogate for 19 
the combined technique remains challenging. Techniques using microbubbles and magnetic 20 
nanoparticles are currently under investigation, with a view to overcome the drawbacks 21 
portended by the radioisotope use and to make the technique more widely available.  22 
Conclusion 23 
The SLNB identification rates are high with all the commonly used blue dyes. Furthermore, 24 
methylene blue is superior to iso-sulphan blue and Patent Blue V with respect to false 25 
negative rates. The combined technique remains the most accurate and effective surgical 26 
technique for SLNB and radioisotope should continue to be used together with blue dye. In 27 
order to standardise the SLNB technique, comparative trials are required to determine the 28 
most effective blue dye for SLNB. National guidelines for SLNB are required in order to 29 
ensure documentation of technique and reporting of adverse events.  30 
13 
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Future perspective 1 
In the future, SLNB may not be offered routinely as currently over 70% of breast cancer 2 
patients are found to be node negative. Until there are significant improvements in axillary 3 
imaging, SLNB will continue to be used routinely for staging early breast cancer.  It is 4 
important that the SLNB technique is standardised and this requires national or 5 
international guidelines. This should also include the minimum dataset required for 6 
appropriate operative documentation to enable subsequent assessment of outcome and for 7 
auditing purposes. The combined technique remains the most accurate and effective 8 
surgical technique for SLNB and radioisotope should continue to be used together with blue 9 
dye. Any future novel SLNB technique should be evaluated against the combined technique 10 
within a randomised controlled trial. The type of blue dye will need be standardised and this 11 
will depend on the most readily available blue dye used at the participating sites. 12 
 13 
Executive Summary 14 
Introduction 15 
 The combined technique is the gold standard for sentinel lymph node biopsy (SLNB), 16 
however there is wide variation in techniques and blue dyes used.  17 
 A systematic review was performed to assess the need for radioisotope and the optimal 18 
blue dye for SLNB. 19 
Methods 20 
 We identified all studies published up to June 2015, evaluating the role of blue dyes for 21 
SLNB in breast cancer and malignant melanoma. 22 
 Studies were considered eligible if they compared a SLNB technique which included blue 23 
dye and reported on the identification and/or complication rates. 24 
Results 25 
 A total of 21 studies were included using Patent Blue V in ten studies, methylene blue in 26 
six studies and iso-sulphan blue in eight studies. 27 
 The combined and blue dye alone techniques had mean identification rates of 28 
95.0±5.7% and 86.2±10.0%. The identification rates of iso-sulphan blue, methylene blue 29 
and Patent Blue V alone were 86.7±9.3%, 92.7±8.4% and 83.2±10.3%. 30 
15 
 
 Lymph node retrieval rates of iso-sulphan blue, methylene blue and Patent Blue V alone 1 
were 1.8±0.4, 1.7±0.2 and 1.5±0.3 nodes and false negative rates were 13.3±2.0%, 2 
6.4±8.2% and 9.9±8.4%.  3 
Discussion 4 
 The blue dye alone technique is inferior to the combined technique.  5 
 Standardisation of procedures is important for future trials comparing novel tracers like 6 
microbubbles and magnetic nanoparticles, against the combined technique. 7 
 There is insufficient evidence to compare the incidence of allergic reactions between the 8 
different blue dyes. 9 
Conclusions 10 
 The SLNB identification rate is high with all the commonly used blue dyes but higher 11 
with the combined technique. Methylene blue is superior to Patent Blue V and iso-12 
sulphan blue with respect to false negative rates.  13 
 In order to standardise the SLNB technique, comparative trials to determine the most 14 
effective blue dye and national guidelines are required. 15 
  16 
16 
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Reference annotations 1 
- Ref 2*: Guidance which are of interest as is states the different types of blue dyes 2 
used for SLNB. 3 
- Ref 24**: A comparative trial, as recommended by our study, comparing methylene 4 
blue with iso-sulphan blue for SLNB in patients with breast cancer. 5 
- Ref 27*: A systematic review in which 69 trials were evaluated performing SLNB 6 
followed by axillary lymph node clearance for early breast cancer. 7 
- Ref 28*: A meta-analysis of 71 studies which used SLNB for staging of malignant 8 
melanoma. 9 
- Ref 39**: A comparative trial, as recommended by our study, comparing methylene 10 
blue with Patent Blue V for SLNB in patients with breast cancer. 11 
- Ref 43**: A comparative trial, as recommended by our study, comparing methylene 12 
blue with iso-sulphan blue for SLNB in patients with malignant melanoma. 13 
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